Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective. Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (hospitalization and outpatient) were extracted for patients with diabetes and a macrovascular complication (1 January 2012-31 December 2018) and converted to US Dollars (2019 USD). Mixed-effects logistic regression explored associations between demographic and clinical characteristics with the incurrence of high direct medical costs. Results: In total, 1,668 (0.2%) patients with diabetes met study inclusion criteria and experienced a macrovascular complication, either alone (N ¼ 1,193) or together with a microvascular complication (N ¼ 475). Median [95% CI] annual costs (USD/patient) were 130.5 [90.7; 264.2] at baseline, increasing to 334.0 [182.2; 923.5] in the first year after the complication. The odds of incurring high costs were significantly elevated in the first and second year (vs. baseline), and in patients who experienced a macrovascular and microvascular complication (vs. macrovascular alone) (all p < 0.001). Limitations: The DATASUS database does not cover primary care (it covers secondary and tertiary care), adding a selection bias to the sample. Additionally, our findings may not be representative of the entire Brazilian population given that approximately 75% of the population of Brazil depend exclusively on the SUS, while the remaining 25% have some access to private healthcare. Conclusions: This study has demonstrated higher medical costs from the perspective of the Brazilian public healthcare system in patients with diabetes after experiencing a macrovascular complication, either alone or in conjunction with a microvascular complication, in comparison with costs before the complication(s). In addition to providing up-to-date cost estimates, our findings highlight the need to implement strategies to reduce the cardiovascular risk in Brazilian patients with diabetes and drive cost savings.

No abstract

A401of which were hysterectomies. Before the launch of UPA in France, number of surgeries increased by 380 each year. The introduction of UPA was correlated with a trend reversal, showing a decrease in the number of surgeries of 1,236 each year from mid-2013. UPA did not have an impact on the type of surgery, neither on the surgical approach. The savings associated with the use of UPA pre-operatively (cost of treatment and avoided surgeries included) were estimated at 2M€ in 2013 and will reach 9M€ in 2016, that was considered as a plateau for the following years. The cumulated budgetary impact from 2016 to 2019 is estimated at -37M€ . ConClusions: Thanks to avoided surgeries, the use of UPA as pre-operative treatment is associated with financial savings, which cover largely the treatment costs. PIH10 Budget-ImPact analysIs (BIa) Of tHe IntrOductIOn Of 52mg levOnOrgestrel-releasIng IntrauterIne system (lng-Ius) as a cOntracePtIve metHOd OPtIOn In tHe BrazIlIan PuBlIc HealtHcare system (sus) tO avOId unIntended Pregnancy (uP) In 15 tO 19 year-Old adOlescents

DA Q3W has the potential to provide cost savings over EA QW in terms of annual average drug cost per patient ($654 savings), per member per year ($839 savings), and total cost per population ($1,471,340 savings). DA Q3W may offer a cost advantage over EA QW as it allows for synchronizing of anemia management with ongoing cancer treatments, which may reduce required patient visits and blood tests.

A383significantly increased from 18% to 25% with carvedilol and bisoprolol versus metoprolol tartrate. Our primary findings were consistent through various sensitivity analyses. ConClusions: We suggest that there is no evidence of a differential effect of β -blockers on mortality in older patients with HF, but the agent selected may have an impact on the rate of HF readmissions.